anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acupuncture is used to lower blood pressure in patients with hypertension, and to relieve angina in patients with coronary artery disease. While the biological mechanisms of acupuncture analgesia have been studied intensely in animals and humans, the biological mechanisms for modulation of the cardiovascular system in humans remain largely unexplored. Acupuncture at traditional acupoints, and at nonacupoints, decreases the blood pressure response during mental stress in normal humans. This depressor effect cannot be fully explained by a decline in muscle sympathetic nerve activity (MSNA). Further, in humans with heart failure (HF) in whom MSNA is elevated, we have preliminary data that acupuncture significantly decreases the MSNA response during mental stress. The following hypotheses will be tested: 1) acupuncture, performed at traditional acupoints and non-acupoints in normal humans, stimulates skeletal muscle afferent neurons causing a release of endogenous opioids, which oppose sympathetic excitation and vasoconstriction in visceral vascular beds, such as the kidney; 2) in humans with HF in whom MSNA is elevated and renal vasoconstriction is the rule, acupuncture utilizes similar mechanisms as in normal humans to produce exaggerated inhibition of MSNA and reflex renal vasoconstriction. Positron emission tomography and microneurography will be utilized to answer the following questions in normal humans and patients with heart failure: 1. Is acupuncture attenuation of BP during mental stress mediated by a decrease in renal vasoconstriction? 2. Is acupuncture sympathoinhibitory? 3. Is acupuncture modulation of the autonomic nervous system mediated by muscle afferents? 4. Is acupuncture modulation of the autonomic nervous system mediated by activation of endogenous opioids? Understanding the mechanisms of acupuncture modulation of the autonomic nervous system in humans may help clarify its role as a therapeutic modality in cardiovascular diseases, such as heart failure.
The body has a number of sensitive surfaces that are subject to injury by physical, chemical and biological agents. The results of injury are, for example, signs of inflammation such as redness, swelling, feeling of heat, pain and loss of function, and discomfort such as itching, irritation, burning sensations, and dysesthesia. The nasal membranes, the ocular surface, the lips and gingiva, and the genital surfaces are examples of such sensitive surfaces. Topical agents can be delivered to these surfaces using pre-medicated single unit applicators, such as swabs, wipes, or cotton-tips attached to handles, but for high frequency use, there is an advantage to using a reservoir bottle of medicated solution together with a packet of single applicators. In this invention, an apparatus embodiment for topically delivering a pharmaceutical comprises a specially designed container, together with a package of single applicators. The desired parameters of drug delivery, namely, precise dosage, hygienic use and storage of the drug solution, single use, and economy for high frequency of use, are provided by the container design. The container accurately up-loads a fixed volume of solution onto the tip of a single applicator; wherein the tip of the applicator is made of an absorbent material such as cotton or rayon. The aperture or opening of the container has a cap that is air-tight when sealed. The diameter of the container aperture is not wider by more than 20% of the maximum width of the applicator tip. The container has a reservoir as an internal capacity to hold 5 to 50 mL of a liquid, and more preferably 5 to 15 mL. At the bottom of the container's reservoir there is a cylindrical cavity, the center of which is aligned perpendicularly to the center of the aperture. The lower wall of the container's reservoir is shaped to funnel the liquid contents of the container to the bottom of the cylindrical cavity formed as a reservoir pocket. This pocket has a concave upward, saucer like, or hemispheric shape to accommodate the tip of the applicator. The length of the container's cylindrical cavity is sufficient to sheath at least 50% of the body of applicator. This apparatus can up-load a single unit applicator with a low coefficient of variation in the up-loaded volume.
The Corazón de la Familia study is a randomized controlled trial conducted to examine if a novel family-focused lifestyle modification intervention is more effective in reducing risk for type 2 diabetes and cardiovascular disease (CVD) than an individual-focused lifestyle modification intervention. We will enroll 220 Hispanic family pairs or dyads, of whom one member has two or more risk factors for type 2 diabetes or CVD but does not have type 2 diabetes or CVD. The second member of the family dyad may or may not have type 2 diabetes or CVD or may or may not be at risk for type 2 diabetes or CVD. Of the 220 family dyads, 110 will be randomly selected to participate in the family-focused intervention and 110 will be randomly selected to participate in the individual-focused intervention. The interventions for both groups will be provided by community health workers. Both groups will receive eight educational sessions about healthy lifestyle behaviors and support to address personal and environmental barriers to engaging in healthy behaviors. After the eight sessions, the community health workers will follow up with participants once a month by phone over the next 12 months. Primary outcomes include short-term and long-term impact of the family-focused active intervention compared to the individual-focused control condition on type 2 diabetes and CVD biological risk factors (for example, blood pressure and weight) and behavioral risk factors (for example, physical activity and tobacco use). Outcomes are measured at baseline, immediately post-intervention, and at the end of the 12 month period of the study for both groups.
The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine used for treating influenza caused by damp toxin, and a preparation method thereof. The medicine is prepared from traditional Chinese medicine materials of, by weight: 10 to 20 parts of roughhaired holly root, 10 to 20 parts of paniculate microcos leaf, 5 to 15 parts of wrinkled gianthyssop herb, 5 to 15 parts of rhizoma crtomii, 5 to 15 parts of aphalangia, 10 to 20 parts of honeysuckle flower, 10 to 20 parts of weeping forsythia fruit, 3 to 9 parts of angelica archang lica, 5 to 15 parts of pennywort, 5 to 15 parts of indigowoad leaf, 10 to 20 parts of reed rhizome, and 3 to 9 parts of chrysanthemum flower. According to the preparation method, the traditional Chinese medicine materials are processed from two-step water extraction, and are spray-dried, such that a traditional Chinese medicine preparation is obtained. According to the invention, a traditional Chinese medicine preparation method is adopted, drug-natures of the medicines are maintained, and the formulation is reasonable. The medicine provides functions of heat clearing, detoxicating, damp dissipating, and illness removing. The medicine can be adopted for clinical use, and can be used for treating influenza caused by damp toxin. The potency and virus resistance of the medicine are good. The medicine brings no toxic or side-effect. Also, the medicine is easy to take.
Curcuma longa, best known for its culinary application as the main constituent of curry powder, has shown potential impact on the reproductive system. This study aimed to investigate the efficacy of Curcuma longa extract (CLE) on Kidney-Yang deficiency mice induced by hydrocortisone and the possible roles in testosterone secretion in Leydig cells. We evaluated male sexual behaviour, reproductive organ weight, testosterone levels, and histological tissue changes in hydrocortisone-induced mice. CLE effectively reversed hydrocortisone-induced Kidney-Yang deficiency syndrome by improving sexual behaviour, testis and epididymis weight, testosterone levels and reducing pathological damage. Our in vitro study further indicated that CLE stimulated testosterone production via upregulating the mRNA and protein expression of steroidogenic enzymes in Leydig cells. It significantly improved H89-inhibited protein expression of StAR and cAMP-response element-binding (CREB), as well as melatonin-suppressed StAR protein expression. The data obtained from this study suggest that CLE could alleviate Kidney-Yang deficiency symptoms and stimulate testosterone production by upregulating the steroidogenic pathway. This research identifies CLE as a potential nutraceutical option for addressing testosterone deficiency diseases.
Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
Diabetic nephropathy (DN) is one of the most important comorbidities for diabetic patients, which is the main factor leading to end-stage renal disease. Heparin analogs can delay the progression of DN, but the mechanism is not fully understood. In this study, we found that low molecular weight heparin therapy significantly upregulated some downstream proteins of the peroxisome proliferator-activated receptor (PPAR) signaling pathway by label-free quantification of the mouse kidney proteome. Through cell model verification, low molecular weight heparin can protect the heparan sulfate of renal tubular epithelial cells from being degraded by heparanase that is highly expressed in a high-glucose environment, enhance the endocytic recruitment of fatty acid-binding protein 1, a coactivator of the PPAR pathway, and then regulate the activation level of intracellular PPAR. In addition, we have elucidated for the first time the molecular mechanism of heparan sulfate and fatty acid-binding protein 1 interaction. These findings provide new insights into understanding the role of heparin in the pathogenesis of DN and developing corresponding treatments.
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and application thereof in preparing a medicine for treating rhinitis. The traditional Chinese medicine composition provided by the invention comprises magnolia flower, ligusticum, mulberry leaf, liquorice and purslane, and the medicinal materials are compounded according to a certain proportion, so that the expression of key inflammatory factors IL-6 and IL-1 beta can be obviously inhibited, and the content of nitric oxide, a vascular endothelial relaxation factor, can be inhibited. Therefore, the composition has the function of treating rhinitis or assisting in treating the rhinitis. The traditional Chinese medicine composition provided by the invention has the main functional indications that: disperse cold, relieve stuffy nose. It is suitable for rhinitis and allergic rhinitis, and has clinical manifestations of continuous sneezing, rhinocnesmus, nasal obstruction, rhinorrhea, etc. caused by pollen, dust mite, cold air, etc.
Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
PURPOSE:To obtain a preventive and therapeutic agent for hypofunction of an organ caused by operation or transplant of the organ, containing a compound having an endoserine receptor antagonism. CONSTITUTION:A cyclic peptide of the formula (X and Y are each an alpha-amino acid residue; A is a D-acidic-alpha-amino acid residue; B is a neutral alpha-amino acid residue; C is an L-alpha-amino acid residue; D is a D-alpha-amino acid residue containing an aromatic ring) or its salt is contained as the active component. As the compound of the formula, cyclo{D-aspartic acid-N<4>-[20(indol-3-yl)ethyl-asparagine- aspartic acid-D-leucine-leucine-D-tryptophan} is exemplified. This medicine is useful for therapy and prevention of hypofunction of an organ such as the liver, the kidney, the heart, the lien or the pancreas, especially the liver. In the case of parenteral administration, e.g. injection, the dosage is 0.01 to 100mg/kg per one operation. In the case of oral administration, it is 5mg to 1g/kg.
During training stages in order to prepare for an important event, sleep and recuperation are almost equally important as the appropriate training strategy. This training strategy often consists of living-high (sleeping at -stimulated- altitude) and training low (training at sea level). A decreased oxygen availability, also known as hypoxia, however often disrupts sleep quality and thus compromises the overall training efficiency. Ketones are recently found to improve sleep quality, thus potentially playing a pivotal role in altitude training. Therefore, the investigators want to evaluate the effects of ketones on sleep in hypoxia, after training in normoxia. Moreover, the effect on a performance test, during a simulated 30 min time trial on the next morning, will be investigated. During this protocol, cerebral blood flow will be assessed, as well as ventilation, blood and tissue oxygen status, heart rate variability, and cognitive function.
Lapatinib in combination with capecitabine is a standard of care treatment for ErbB2+ metastatic breast cancer (MBC) patients who have progressed after anthracyclines, taxanes and trastuzumab treatment. Results from the lapatinib pivotal trial showed that the addition of lapatinib to capecitabine increased median time to progression (TTP) even among heavily pre-treated patients (median of 4 prior lines of therapy). A recent ad hoc subset analysis of this trial suggested that earlier administration of lapatinib-capecitabine in MBC patients who progress after trastuzumab may produce better clinical outcomes. The TYCO study was designed to evaluate if early switch to lapatinib-capecitabine in patients with ErbB2+ MBC who have progressed on trastuzumab-containing regimen improves TTP in comparison with a later start (after several lines of therapy). Secondary objectives include Overall Response Rate (ORR), 1 year Overall Survival (OS), and description of reported serious adverse events. This is an international, multicenter, prospective, observational (non-interventional) study in 269 ErbB2+MBC patients whose disease has progressed after treatment with trastuzumab. Two cohorts will be compared; Group 1: patients receiving lapatinib-capecitabine immediately after first trastuzumab progression, and Group 2: patients receiving lapatinib-capecitabine after two or more lines of treatment after first trastuzumab progression. Eligibility criteria include females aged 18 or more with confirmed ErbB2+ MBC who have progressed after a previous trastuzumab-containing regimen, eligible to start standard therapy with lapatinib-capecitabine at approved conventional doses, as per local label approval. The study duration is of 12 months with data collection at baseline and approximately every 3 months thereafter. Patient evaluations will be conducted per standard patient care in each center and TTP will be determined by the treating physician (clinically or radiologically). Enrollment started in February 2010 and completion of accrual is estimated for December 2011.
INTRODUCTION: Impaired upper limb movements are a key feature in dyskinetic cerebral palsy (CP). However, information on how specific movement patterns relate to manual ability, performance and underlying movement disorders is lacking. Insight in these associations may contribute to targeted upper limb management in dyskinetic CP. This study aimed to explore associations between deviant upper limb movement patterns and (1) manual ability, (2) severity of dystonia/choreoathetosis, and (3) movement time/trajectory deviation during reaching and grasping.
PARTICIPANTS/METHODS: Participants underwent three-dimensional upper limb analysis during reaching forwards (RF), reaching sideways (RS) and reach-and-grasp vertical (RGV) as well as clinical assessment. Canonical correlation and regression analysis with statistical parametric mapping were used to explore associations between clinical/performance parameters and movement patterns (mean and variability).
RESULTS: Thirty individuals with dyskinetic CP participated (mean age 16±5 y; 20 girls). Lower manual ability was related to higher variability in wrist flexion/extension during RF and RS early in the reaching cycle (p < 0.05). Higher dystonia severity was associated with higher mean wrist flexion (40-82 % of the reaching cycle; p = 0.004) and higher variability in wrist flexion/extension (31-75 %; p < 0.001) and deviation (2-14 %; p = 0.007/60-73 %; p = 0.006) during RF. Choreoathetosis severity was associated with higher elbow pro/supination variability (12-19 %; p = 0.009) during RGV. Trajectory deviation was associated with wrist and elbow movement variability (p < 0.05).
CONCLUSION: Current novel analysis of upper limb movement patterns and respective timings allows to detect joint angles and periods in the movement cycle wherein associations with clinical parameters occur. These associations are not present at each joint level, nor during the full movement cycle. This knowledge should be considered for individualized treatment strategies.
All patients were intended to engage in three different 20-30 min sessions run by research coordinators and spaced a minimum of 4 hours apart to allow for washout of effects, including 1) a commercially available, immersive VR environment, theBlu (WEVR, Inc, Venice, California, USA) delivered via Oculus Rift (Oculus VR, Irvine, California, USA) headset (VR Blu), 2) a non-immersive two-dimensional mimic delivered via a tablet computer (Tablet Blu), and 3) a VR control session delivered via a content-less Oculus Rift headset (VR Blank). The three sessions were run by research coordinators and spaced a minimum of 4 hours apart. The intervention order was counterbalanced using a randomized sequence generator.
The invention relates to a carnauba wax-containing valnemulin injection with latex-like appearance. Each liter of the injection comprises 150-180g of valnemulin hydrochloride, 2.5-11g of carnauba wax, and the balance of glyceryl triacetate/benzyl benzoate/1,2-propylene glycol/ethanol with a volume ratio of 4.5:3:3.3:1. Each of the injection also comprises 100-150ml of glyceryl monooleate. In the preparation process of 1L of the injection, 13.0-31.2g of sodium citrate dihydrate (C6H5Na3O7.2H2O) or 19.0-31.9g of sodium carbonate decahydrate (Na2CO3.10H2O) is added. Added sodium citrate or sodium carbonate reacts with valnemulin hydrochloride. Each liter of the injection prepared in the invention includes 150-180g of valnemulin alkali and valnemulin acid salt (hydrochloride or citrate), 2.5-11g of carnauba wax, 100-150ml of glyceryl monooleate, and the balance of glyceryl triacetate/benzyl benzoate/1,2-propylene glycol/ethanol with a volume ratio of 4.5:3:3.3:1.
PURPOSE OF REVIEW: Immune-mediated necrotizing myopathy (IMNM), characterized by acute or subacute onset, severe weakness, and elevated creatine kinase levels, poses diagnostic and therapeutic challenges. This article provides a succinct overview of IMNM, including clinical features, diagnostic strategies, and treatment approaches.
RECENT FINDINGS: Recent insights highlight the different clinical presentations and therapeutic options of IMNM stratified by autoantibody positivity and type. Additionally, recent findings call into question the reported link between statin use and IMNM. This review synthesizes current knowledge on IMNM, emphasizing its distinct clinical features and challenging management. The evolving understanding of IMNM underscores the need for a comprehensive diagnostic approach that utilizes a growing range of modalities. Early and aggressive immunomodulatory therapy remains pivotal. Ongoing research aims to refine diagnostic tools and therapeutic interventions for this challenging muscle disorder, underscoring the importance of advancing our understanding to enhance patient outcomes.
Pain is the main reason why SCD patients are admitted and readmitted to the hospital. In fact, readmission rates of SCD patients are higher than those of asthmatics and diabetics. In order to reduce 30-day hospital readmission rates and improve patient care quality, the Affordable Care Act and Centers for Medicare and Medicaid Services have established the Readmissions Reduction Program. In keeping with this effort, the investigators propose a methodology and supporting technology that has the potential to change the way SCD patients are monitored after hospital discharge and in turn, decrease readmission rates. This methodology also has the potential to enhance the quality of life of SCD patients by improving patient reporting, self-efficacy, and increasing patient/provider engagement when there is worsening pain and increased admission/readmission risk. This software platform uses validated Patient Reported Outcome Measurement Information System (PROMIS) measures to remotely monitor SCD patients' pain and related outcomes after hospital discharge. With this initial study, the investigators propose to use this monitoring platform to identify the predictors of readmission, to develop a readmission prediction engine, and to design the next version of the app with built in interventions to address those readmission risks. This monitoring platform could also increase healthcare provider engagement when there is a worsening of patients' pain and/or an increased risk of readmission. In order to build and optimize this monitoring platform, the investigators have assembled a team of engineers, hematologists, pain researchers, and statisticians that have worked together, and who collectively have the expertise to develop and test the feasibility and predictive value of the application in a large population of SCD patients.
The treatments will be initiated as soon as possible after randomization (maximum 12h). Patients will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician. Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
Inclusion criteria were: women attended in the outpatient clinic with baseline exams before ART and during ovarian stimulation between July 2021 and July 2023. Exclusion criteria were: patients with known clinical hypothyroidism, patients using medications that may influence the hypothalamic-pituitary-thyroid axis, such as glucocorticoids in supraphysiological doses; or that could interfere with thyroid hormone metabolism (lithium, amiodarone and aspirin in anti-inflammatory dosages).